323 related articles for article (PubMed ID: 16930142)
1. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
2. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.
Mylin AK; Abildgaard N; Johansen JS; Andersen NF; Heickendorff L; Standal T; Gimsing P; Knudsen LM
Eur J Haematol; 2008 Apr; 80(4):310-7. PubMed ID: 18182077
[TBL] [Abstract][Full Text] [Related]
3. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
5. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
6. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
7. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
8. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
[TBL] [Abstract][Full Text] [Related]
9. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
10. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
13. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
14. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
[TBL] [Abstract][Full Text] [Related]
15. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.
Johansen JS; Lottenburger T; Nielsen HJ; Jensen JE; Svendsen MN; Kollerup G; Christensen IJ
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2603-8. PubMed ID: 18843001
[TBL] [Abstract][Full Text] [Related]
16. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.
Mylin AK; Abildgaard N; Johansen JS; Heickendorff L; Kreiner S; Waage A; Turesson I; Gimsing P;
Leuk Lymphoma; 2015; 56(9):2650-9. PubMed ID: 25573204
[TBL] [Abstract][Full Text] [Related]
17. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
18. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.
Mylin AK; Andersen NF; Johansen JS; Abildgaard N; Heickendorff L; Standal T; Gimsing P; Knudsen LM
Int J Cancer; 2009 Mar; 124(6):1492-4. PubMed ID: 19089918
[No Abstract] [Full Text] [Related]
20. [The importance of determining the prognostic marker YKL-40 in serum and tissues].
Łata E; Gisterek I; Matkowski R; Szelachowska J; Kornafel J
Pol Merkur Lekarski; 2010 Jun; 28(168):505-8. PubMed ID: 20642115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
